Hims, Super Bowl and Hers

Hims & Hers Stock Soars on Momentum From Super Bowl Ad, RFK Confirmation
Shares of Hims & Hers Health, the telehealth provider that has found a niche in the obesity-drug boom, surged 28% on Thursday as the company’s [controversial Super Bowl ad](
HIMS Stock Hits New ATH After Successful Super Bowl Ad
Hims & Hers Health (HIMS) stock hit a new all-time high on Thursday as retail investors have taken interest in the telehealth company. A
Hims & Hers' Super Bowl ad turns up the heat on GLP-1 battle
Hims & Hers hit the bullseye with its Super Bowl ad, sparking a surge in clicks to its site.The ad also hit a nerve with the pharma industry, lawmakers and some industry groups. | Hims & Hers hit the bullseye with its Super Bowl ad,
Super Bowl ad for Hims & Hers' weight loss drug sparks backlash
The ad goes on to tout Hims & Hers' weight loss drugs as less expensive alternatives to medications like Ozempic and Wegovy, which both contain the active ingredient semaglutide and are approved by the U.S. Food and Drug Administration to treat Type 2 diabetes and obesity, respectively.
Hims & Hers aired a Super Bowl ad for weight loss drugs. It alarmed health experts and senators.
NBC News’ Kate Snow talks with hairdresser Hector Corvera who was diagnosed with bladder cancer in 2023. He is the plaintiff in a new lawsuit that alleges his cancer is because of the ingredients in hair dye he was exposed to through his work.
Hims & Hers Super Bowl Spot Draws Drug-Industry Backlash
Telehealth provider Hims & Hers Health is defending its planned Super Bowl ad, which is styled as a political manifesto against weight-loss treatments priced “for profits, not patients,” after critici
What is compounded semaglutide and is it safe? The weight loss drugs Hims & Hers is selling, explained.
Compounded semaglutide is legal, but it's not regulated in the same way as medications like Ozempic and Wegovy.
Hims & Hers stock sees another spike in trading days after Super Bowl ad
Telehealth stock Hims & Hers spiked more than 24% in trading Thursday, days after its Super Bowl ad promoting cheaper GLP-1 weight-loss drugs sparked controversy. The ad criticize
Why Hims & Hers Health Inc. (HIMS) Went Up on Thursday
We recently published a list of 10 Firms Post Double-Digit Gains on Thursday. In this article, we are going to take a look at ...
Hims & Hers: Firing On All Cylinders, But Expensive
Hims & Hers has shown impressive revenue growth, accelerating from 46% to 77%. Read why I downgrade HIMS stock from buy to ...
Fast Company3d
Hims & Hers markets itself in a very 2025 way: by picking a fight
In its recent Super Bowl ad, the telehealth provider Hims & Hers went on the attack against something bigger: “the system.” Promoting a weight-loss drug positioned as a cheaper Ozempic ...
Hosted on MSN2d
Hims & Hers Health (HIMS) Surges 27.7%: Is This an Indication of Further Gains?
Hims & Hers Health, Inc. (HIMS) shares rallied 27.7% in the last trading session to close at $59.18. This move can be attributable to notable volume with a higher number of shares being traded than in ...
GLP-1 ad battle—Ozempic and Wegovy maker responds to Hims & Hers Super Bowl debut
Ozempic and Wegovy maker Novo Nordisk placed a print ad responding to the Super Bowl spot from competitor Hims & Hers.